To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
研究单位：[1]Incyte Corporation[2]Peking University People'S Hospital (Pkuph) - Institute of Hematology Beijing,China,100044[3]Xuanwu Hospital Capital Medical University Beijing,China,100053[4]Peking University Third Hospital Beijing,China,100091[5]Peking University Third Hospital Beijing,China,100191[6]The First Hospital of Jilin University Changchun,China,130021[7]The First Peoples Hospital of Changzhou Changzhou,China,213003[8]Fujian Medical University Union Hospital Fuzhou,China,350001[9]Nanfang Hospital Guangzhou,China,510515
研究目的：
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.
